Market Overview

UPDATE: Credit Suisse Initiates Spectrum Pharmaceuticals at Neutral; Lacking Fusilev Visibility

Related SPPI
H.C. Wainwright & Co. Sees Significant Upside Ahead For Spectrum Pharmaceuticals
Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)

Credit Suisse initiated coverage on Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) with a Neutral rating and a $15.00 price target.

Credit Suisse said, "SPPI is successfully building an oncology-specific, multiproduct company, with a strong focus on sustained profitability and returning value to shareholders. In H1:13, investors will be primarily focused on Fusilev sales and the impact of increased competition from generic leucovorin. Sales of Fusilev may decrease from 2012 highs and limit near-term stock performance. We prefer to take a wait-and-see approach and would look to buy SPPI with greater visibility on Fusilev. From a valuation perspective, we think that shares already reflect a reduction in Fusilev though consensus sales estimates remain high for 2013."

Spectrum Pharmaceuticals closed at $12.67 on Monday.

Latest Ratings for SPPI

DateFirmActionFromTo
Oct 2013HC WainwrightInitiates Coverage onBuy
Jul 2013JMP SecuritiesUpgradesMarket PerformMarket Outperform
Jun 2013Credit SuisseDowngradesNeutralUnderperform

View More Analyst Ratings for SPPI
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (SPPI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters